Literature DB >> 22445213

Mechanism of inactivation of ocriplasmin in porcine vitreous.

Frans Aerts1, Bernard Noppen, Laetitia Fonteyn, Rita Derua, Etienne Waelkens, Marc D de Smet, Marc Vanhove.   

Abstract

Ocriplasmin, a 249-amino acid recombinant C-terminal fragment of human plasmin, has the potential to degrade, within the eye, the protein scaffold that links the vitreous to the retina. This may be beneficial to the treatment of a number of important ophthalmic indications, such as symptomatic vitreomacular adhesion. We demonstrate here that ocriplasmin used at therapeutically-relevant concentrations is inactivated in porcine vitreous through autolytic degradation. Autolytic cleavage occurs at a limited number of sites, primarily K156-E157, K166-V167 and R177-V178, which, as predicted, contain a positively-charged arginine or lysine residue at the P1 position. Our data also suggest that autolytic degradation requires at least local or partial unfolding of the protein.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445213     DOI: 10.1016/j.bpc.2012.03.002

Source DB:  PubMed          Journal:  Biophys Chem        ISSN: 0301-4622            Impact factor:   2.352


  6 in total

Review 1.  Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion.

Authors:  Yahiya Y Syed; Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

2.  Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries.

Authors:  Puya Gharahkhani; Eric Jorgenson; Pirro Hysi; Anthony P Khawaja; Sarah Pendergrass; Xikun Han; Jue Sheng Ong; Alex W Hewitt; Ayellet V Segrè; John M Rouhana; Andrew R Hamel; Robert P Igo; Helene Choquet; Ayub Qassim; Navya S Josyula; Jessica N Cooke Bailey; Pieter W M Bonnemaijer; Adriana Iglesias; Owen M Siggs; Terri L Young; Veronique Vitart; Alberta A H J Thiadens; Juha Karjalainen; Steffen Uebe; Ronald B Melles; K Saidas Nair; Robert Luben; Mark Simcoe; Nishani Amersinghe; Angela J Cree; Rene Hohn; Alicia Poplawski; Li Jia Chen; Shi-Song Rong; Tin Aung; Eranga Nishanthie Vithana; Gen Tamiya; Yukihiro Shiga; Masayuki Yamamoto; Toru Nakazawa; Hannah Currant; Ewan Birney; Xin Wang; Adam Auton; Michelle K Lupton; Nicholas G Martin; Adeyinka Ashaye; Olusola Olawoye; Susan E Williams; Stephen Akafo; Michele Ramsay; Kazuki Hashimoto; Yoichiro Kamatani; Masato Akiyama; Yukihide Momozawa; Paul J Foster; Peng T Khaw; James E Morgan; Nicholas G Strouthidis; Peter Kraft; Jae H Kang; Chi Pui Pang; Francesca Pasutto; Paul Mitchell; Andrew J Lotery; Aarno Palotie; Cornelia van Duijn; Jonathan L Haines; Chris Hammond; Louis R Pasquale; Caroline C W Klaver; Michael Hauser; Chiea Chuen Khor; David A Mackey; Michiaki Kubo; Ching-Yu Cheng; Jamie E Craig; Stuart MacGregor; Janey L Wiggs
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

3.  Rhegmatogenous retinal detachment following intravitreal ocriplasmin.

Authors:  Haifa A Madi; Richard J Haynes; Diana Depla; Morten D de la Cour; Sarit Lesnik-Oberstein; Mahi M K Muqit; Niall Patton; Nick Price; David H W Steel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-08       Impact factor: 3.117

4.  Mutational Analysis of Ocriplasmin to Reduce Proteolytic and Autolytic Activity in Pichia pastoris.

Authors:  Roghayyeh Baghban; Safar Farajnia; Younes Ghasemi; Reyhaneh Hoseinpoor; Azam Safary; Mojtaba Mortazavi; Nosratollah Zarghami
Journal:  Biol Proced Online       Date:  2020-12-13       Impact factor: 3.244

5.  Engineering of Ocriplasmin Variants by Bioinformatics Methods for the Reduction of Proteolytic and Autolytic Activities.

Authors:  Roghayyeh Baghban; Safar Farajnia; Younes Ghasemi; Mojtaba Mortazavi; Samaneh Ghasemali; Mostafa Zakariazadeh; Nosratollah Zarghami; Nasser Samadi
Journal:  Iran J Med Sci       Date:  2021-11

6.  Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149.

Authors:  Marc Vanhove; Bernard Noppen; Jean-Marc Wagner; Tine Van Bergen; Philippe Barbeaux; Alan W Stitt
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-07-23       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.